Top

Published in:

01-12-2014 | Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches

Authors: Jennifer L. Brown, Jessica M. Sales, Ralph J. DiClemente

Published in: Current HIV/AIDS Reports | Issue 4/2014

Abstract

Combination HIV prevention interventions that integrate efficacious behavioral and biomedical strategies offer the potential to reduce new HIV infections. We overview the efficacy data for three biomedical HIV prevention approaches, namely microbicides, pre-exposure prophylaxis (PrEP), and HIV vaccination; review factors associated with differential acceptability and uptake of these methods; and suggest strategies to optimize the effectiveness and dissemination of combination HIV prevention approaches. A narrative review was conducted highlighting key efficacy data for microbicides, PrEP, and an HIV vaccination and summarizing acceptability data for each of the three biomedical HIV prevention approaches. Recommendations for the integration and dissemination of combined behavioral and biomedical HIV prevention approaches are provided. To date, microbicides and an HIV vaccination have demonstrated limited efficacy for the prevention of HIV. However, PrEP has demonstrated efficacy in reducing HIV incident infections. A diverse array of factors influences both hypothetical willingness and actual usage of each biomedical prevention method. Strategies to effectively integrate and evaluate combination HIV prevention interventions are urgently needed.

CDC. Estimated HIV incidence among adults and adolescents in the United States, 2007–2010. HIV Surveillance Supplemental Report 2012, 17.

WHO. Core epidemiological slides: HIV/AIDS estimates. 2013.

3.•

Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8:62–72. This article overviews potential strategies to develop, evaluate, and implement combination HIV prevention approaches and notes currently funded combination HIV prevention trials.PubMedCentralPubMedCrossRef

Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, et al. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS ONE. 2013;8:1–13.CrossRef

Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301.PubMedCrossRef

6.•

Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010;24:S70–80. This paper describes strategies for implementation of combination HIV prevention approaches at different system levels which are tailored to a particular culture.PubMedCrossRef

CDC. Effective interventions: HIV prevention that works. Atlanta: CDC; 2014.

Galbraith JS, Herbst JH, Whittier DK, Jones PL, Smith BD, Uhl G, et al. Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention. Health Educ Res. 2011;26:872–85.PubMedCrossRef

Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health. 2004;94:1159–64.PubMedCentralPubMedCrossRef

10.

Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis. 2008;8:685–97.PubMedCentralPubMedCrossRef

11.

Obiero J, Mwethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC Infect Dis. 2012;12:289.PubMedCentralPubMedCrossRef

12.

Mantell JE, Myer L, Carballo-Diéguez A, Stein Z, Ramjee G, Morar NS, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60:319–30.PubMedCrossRef

13.

Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care. 2008;20:106–15.PubMedCrossRef

14.

Weeks MR, Mosack KE, Abbott M, Sylla LN, Valdes B, Prince M. Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis. 2004;31:682–90.PubMedCentralPubMedCrossRef

15.

Mantell JE, Morar NS, Myer L, Ramjee G. ‘We have our protector’: misperceptions of protection against HIV among participants in a microbicide efficacy trial. Am J Public Health. 2006;96:1073–7.PubMedCentralPubMedCrossRef

16.

Rustomjee R, Karim QA, Abdool Karim SS, Laga M, Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS. 1999;13:1511–5.PubMedCrossRef

17.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006;20:1109–16.PubMedCrossRef

18.

Woodsong C, Alleman P. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev. 2008;20:171–87.PubMedCrossRef

19.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr. 2000;2003(33):476–83.

20.

Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Women’s Health. 2003;12:655.CrossRef

21.

van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012;16:1775–86.PubMedCrossRef

22.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.PubMedCentralPubMedCrossRef

23.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–51.PubMedCrossRef

24.

Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Women’s Health. 2008;17:383–92.CrossRef

25.

Morrow KM, Ruiz MS. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 2008;12:272–83.PubMedCentralPubMedCrossRef

26.

Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;18:195–216.PubMedCentralPubMedCrossRef

27.

FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Edited by U.S. Department of Health and Human Services. Silver Spring, MD; 2012.

28.

Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.PubMedCentralPubMedCrossRef

29.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.PubMedCrossRef

30.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.PubMedCentralPubMedCrossRef

31.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.PubMedCentralPubMedCrossRef

32.

Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs. 2010;24:689–91.PubMedCrossRef

33.

Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77–83.PubMedCentralPubMedCrossRef

34.

Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54:548–55.PubMedCentralPubMedCrossRef

35.

Underhill K, Morrow KM, Operario D, Mayer KH. Could FDA approval of pre-exposure prophylaxis make a difference? A qualitative study of PrEP acceptability and FDA perceptions among men who have sex with men. AIDS Behav. 2014;18:241–9.PubMedCrossRef

36.

Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall J-M, Cook E, et al. Acceptability of an “on-demand” pre-exposure HIV prophylaxis trial among men who have sex with men living in France. AIDS Care. 2012;24:468–77.PubMed

37.

Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee S-J, Leibowitz AA. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011;23:1136–45.PubMedCentralPubMedCrossRef

38.

Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee S-J, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDs. 2012;26:87–94.PubMedCentralPubMedCrossRef

39.

Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLos ONE. 2012;7:e28238.PubMedCentralPubMedCrossRef

40.

Galea JT, Kinsler JJ, Salazar X, Lee SJ, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.PubMedCentralPubMedCrossRef

41.

Schneider J, Kumar R, Dandona R, Kumar P, Kumar A, Lakshmi V, et al. Social network and risk-taking behavior most associated with rapid HIV testing, circumcision, and preexposure prophylaxis acceptability among high-risk Indian men. AIDS Patient Care STDs. 2012;26:631–40.PubMedCentralPubMedCrossRef

42.

Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDs. 2012;26:222–33.PubMed

43.

Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24:408–21.PubMedCrossRef

44.

Tellalian D, Maznavi K, Bredeek F, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDs. 2013;27:553–9.PubMedCrossRef

45.

Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.PubMedCentralPubMedCrossRef

46.

Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Acceptability of PrEP for HIV prevention among women at high risk for HIV. J Women’s Health. 2010;19:791–8.CrossRef

47.

Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17:2162–72.PubMedCentralPubMedCrossRef

48.

Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLos ONE. 2012;7:e33103.PubMedCentralPubMedCrossRef

49.

Heffron R, Ngure K, Mugo N, Celum C, Kurth A, Curran K, et al. Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr. 2012;61:116–9.PubMedCentralPubMedCrossRef

50.

Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59:463–8.PubMedCrossRef

51.

Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLos ONE. 2013;8:e74314.PubMedCentralPubMedCrossRef

52.

Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17:737–47.PubMedCentralPubMedCrossRef

53.

Dolin R. HIV vaccine trial results—an opening for further research. N Engl J Med. 2009;361:2279–80.PubMedCrossRef

54.

Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23:1430–47.PubMedCrossRef

55.

Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18:2235–42.PubMedCrossRef

56.

Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010;24:1749–56.PubMedCrossRef

57.

Jaspan HB, Berwick JR, Myer L, Mathews C, Flisher AJ, Wood R, et al. Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials. J Adolesc Health. 2006;39:642–8.PubMedCrossRef

58.

Sayles JN, Macphail CL, Newman PA, Cunningham WE. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav. 2010;37:193–210.PubMedCentralPubMedCrossRef

59.

Webb PM, Zimet GD, Mays R, Fortenberry JD. HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health. 1999;25:320–2.PubMedCrossRef

60.

Liau A, Zimet GD. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care. 2001;13:643–50.PubMedCrossRef

61.

Liau A, Zimet GD. Undergraduates’ perception of HIV immunization: attitudes and behaviours as determining factors. Int J STD AIDS. 2000;11:445–50.PubMedCrossRef

62.

Ravert RD, Zimet GD. College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav. 2009;33:391–9.PubMedCrossRef

63.

Newman PA, Woodford MR, Logie C. HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2012;7:87–100.PubMedCrossRef

64.

Lee S-J, Brooks RA, Newman PA, Seiden D, Sangthong R, Duan N. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care. 2008;20:1161–8.PubMedCentralPubMedCrossRef

65.

Li Q, Luo F, Zhou Z, Li S, Liu Y, Li D, et al. Willingness to participate in HIV vaccine clinical trials among Chinese men who have sex with men. Vaccine. 2010;28:4638–43.PubMedCrossRef

66.

Newman PA, Roungprakhon S, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28:958–64.PubMedCrossRef

67.

Kakinami L, Newman PA, Lee S-J, Duan N. Differences in HIV vaccine acceptability between genders. AIDS Care. 2008;20:542–6.PubMedCentralPubMedCrossRef

68.

Newman PA, Duan N, Lee S-J, Rudy ET, Seiden DS, Kakinami L, et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine. 2006;24:2094–101.PubMedCentralPubMedCrossRef

69.

Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17:253–67.PubMedCrossRef

70.

Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine. 2008;26:2528–36.PubMedCentralPubMedCrossRef

71.

Strauss RP, Sengupta S. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. Communities. J Acquir Immune Defic Syndr. 2001;26:63.PubMedCrossRef

72.

Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41:210–7.PubMedCrossRef

73.

Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604–12.PubMedCrossRef

74.

Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359–64.PubMedCrossRef

75.

Dhawan D, Mayer KH. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis. 2006;193:36–44.PubMedCrossRef

76.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, et al. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials. 2011;12:67.PubMedCentralPubMedCrossRef

77.

Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH. Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep. 2010;7:210–9.PubMedCentralPubMedCrossRef

78.

Curran JW, Crosby RA. Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges? Am J Prev Med. 2013;44:S163–6.PubMedCrossRef

79.

Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8:94–103.PubMedCentralPubMedCrossRef

80.

Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A. 2008;105:9835–40.PubMedCentralPubMedCrossRef

81.

Cohen MS, Baden LR. Preexposure prophylaxis for HIV—where do we go from here? N Engl J Med. 2012;367:459–61.PubMedCrossRef

82.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26:F13–9.PubMedCrossRef

83.

Mills E, Nixon S, Singh S, Dolma S, Nayyar A, Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLos Med. 2006;3:e94.PubMedCentralPubMedCrossRef

84.

Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;62:447–56.PubMedCrossRef

85.

Katz MH. Pre-exposure prophylaxis for HIV: can it be implemented in the real world? Am J Prev Med. 2013;44:S161–2.PubMedCrossRef

86.

Warren MJ, Bass ES. From efficacy to impact: an advocate’s agenda for HIV pre-exposure prophylaxis implementation. Am J Prev Med. 2013;44:S167–70.PubMedCrossRef

Title: Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches
Authors: Jennifer L. Brown
Jessica M. Sales
Ralph J. DiClemente
Publication date: 01-12-2014
Publisher: Springer US
Published in: Current HIV/AIDS Reports / Issue 4/2014
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-014-0228-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Realizing the Potential of Treatment as Prevention: Global ART Policy and Treatment Coverage

Reaching the Unreached: Treatment as Prevention as a Workable Strategy to Mitigate HIV and Its Consequences in High-Risk Groups

Review of Recent Behavioral Interventions Targeting Older Adults Living with HIV/AIDS

Advances in HIV Prevention for Serodiscordant Couples

Cost-effectiveness Analysis Along the Continuum of HIV Care: How Can We Optimize the Effect of HIV Treatment as Prevention Programs?

Modeling the Implementation of Universal Coverage for HIV Treatment as Prevention and its Impact on the HIV Epidemic

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials